Loading
A small trial in ten people with advanced melanoma that compared how long infused T cells lasted with and without the chemotherapy drug fludarabine first. Fludarabine made them last about three times longer.
In a first-in-human phase I study (FHCRC 1796, NCT00317759), patients with refractory metastatic melanoma received two infusions of a single tumour-reactive antigen-specific CTL clone, the first without and the second after fludarabine 25 mg/m2 a day for five days, allowing an intra-patient comparison (PLoS ONE 2009). Nineteen infusions were given to ten patients with no serious toxicities (PLoS ONE 2009).
Lymphodepletion before infusion helps transferred T cells survive, but the rise in regulatory T cells suggests conditioning alone is not enough for anti-tumour effect.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/